Funding
AusperBio raises $120M Series C to advance hep B oligo therapy through phase 3
August 28, 2026
Biotech
Funding
Key Facts
Signal Type
Funding
Industry
Biotech
Companies
AusperBio Therapeutics, RA Capital Management, GSK, Ionis Pharmaceuticals, Qiming Venture Partners
Date
August 28, 2026
AusperBio Therapeutics raised $120 million in Series C funding led by RA Capital Management, with participation from HanKang Capital, Qiming Venture Partners, YuanBio Venture Capital, and CDH Investments. The Bay Area biotech is advancing lead candidate AHB-137, an unconjugated antisense oligonucleotide (ASO) for chronic hepatitis B, into Phase 3 testing in China. The round follows a $37M Series A in 2024 and a three-part $186M Series B across 2024-25.
This funding impacts clinical research organizations, lab informatics vendors, and specialty supply chain partners targeting biotech scale-ups. AusperBio is preparing to scale clinical operations, manufacturing, and data infrastructure for Phase 3 and potential commercialization. Competitors like GSK's bepirovirsen (licensed from Ionis) are also advancing in the oligonucleotide space.
Monitor AusperBio's Phase 3 enrollment progress and any partnership announcements for manufacturing or distribution. Also track GSK's bepirovirsen regulatory decisions outside Japan, which could shape market positioning. The siRNA candidate AHB-171's early clinical data will indicate platform expansion potential beyond hepatitis B.
Source:
Fierce BiotechGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
